KROS Cash-Secured Put Strategy
KROS (Keros Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
KROS (Keros Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $351.7M, a beta of 0.97 versus the broader market, a 52-week range of 9.69-22.55, average daily share volume of 335K, a public-listing history dating back to 2020, approximately 163 full-time employees. These structural characteristics shape how KROS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.97 places KROS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a cash-secured put on KROS?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current KROS snapshot
As of June 29, 2026, spot at $10.90, ATM IV 154.20%, IV rank 31.68%, expected move 44.21%. The cash-secured put on KROS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this cash-secured put structure on KROS specifically: KROS IV at 154.20% is mid-range versus its 1-year history, so the credit collected on a KROS cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 44.21% (roughly $4.82 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KROS expiries trade a higher absolute premium for lower per-day decay. Position sizing on KROS should anchor to the underlying notional of $10.90 per share and to the trader's directional view on KROS stock.
KROS cash-secured put setup
The KROS cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KROS near $10.90, the first option leg uses a $10.36 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KROS chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KROS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $10.36 | N/A |
KROS cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
KROS cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on KROS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on KROS
Cash-secured puts on KROS earn premium while a trader waits to acquire KROS stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning KROS.
KROS thesis for this cash-secured put
The market-implied 1-standard-deviation range for KROS extends from approximately $6.08 on the downside to $15.72 on the upside. A KROS cash-secured put lets a trader earn premium while waiting to acquire KROS at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current KROS IV rank near 31.68% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on KROS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, KROS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KROS-specific events.
KROS cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KROS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KROS alongside the broader basket even when KROS-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on KROS carry tail risk when realized volatility exceeds the implied move; review historical KROS earnings reactions and macro stress periods before sizing. Always rebuild the position from current KROS chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on KROS?
- A cash-secured put on KROS is the cash-secured put strategy applied to KROS (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With KROS stock trading near $10.90, the strikes shown on this page are snapped to the nearest listed KROS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are KROS cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the KROS cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 154.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a KROS cash-secured put?
- The breakeven for the KROS cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KROS market-implied 1-standard-deviation expected move is approximately 44.21%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on KROS?
- Cash-secured puts on KROS earn premium while a trader waits to acquire KROS stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning KROS.
- How does current KROS implied volatility affect this cash-secured put?
- KROS ATM IV is at 154.20% with IV rank near 31.68%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.